Clinical Takeaway
Cannabinoid-based treatments, including CBD-rich preparations, have shown early promise for reducing certain behavioral symptoms in autism spectrum disorder, such as irritability, hyperactivity, and sleep disturbances. The evidence comes from a small number of randomized controlled trials, so findings should be interpreted cautiously. Larger, well-designed studies are needed before cannabinoid therapies can be broadly recommended for ASD management.
#14 Therapeutic Use of Cannabis Derivatives and Their Analogs for Autism Spectrum Disorder: A Systematic Review.
Citation: Riera Rachel et al.. Therapeutic Use of Cannabis Derivatives and Their Analogs for Autism Spectrum Disorder: A Systematic Review.. Journal of clinical pharmacology. 2025. PMID: 40605143.
Design: 5 Journal: 0 N: 0 Recency: 2 Pop: 3 Human: 1 Risk: 0
This systematic review synthesizes evidence from randomized controlled trials on cannabis derivatives for autism spectrum disorder, addressing a significant gap in evidence-based treatment options for core symptoms and associated behavioral challenges in this population. Given the limited efficacy of current pharmacological interventions for autism’s social communication and behavioral domains, establishing the safety and efficacy profile of cannabinoid-based therapeutics could expand the clinical armamentarium for symptom management. The methodological rigor of this Cochrane-aligned review provides clinicians with a credible evidence synthesis to inform treatment decisions and identify areas requiring further investigation before broader clinical implementation.
Abstract: Autism spectrum disorders are characterized by some difficulties with social interactions and communication, atypical patterns of behavior, and unusual reactions to emotions. Studies have found promising results regarding the effects of cannabis on autism. We conducted a systematic review of randomized clinical trials on the effects of cannabis derivatives and their analogs for autism. This review was developed according to the Cochrane Handbook for Systematic Reviews of Interventions and reported according to PRISMA 2020. The protocol was prospectively published in the PROSPERO database (CRD42023468300). We included randomized controlled trials with autism-diagnosed participants treated with any cannabis derivate or its analogs for therapeutic purposes. Two reviewers assessed titles and abstracts independently and potentially eligible full texts were assessed to confirm eligibility. After that, they extracted data using a standardized worksheet. Searches retrieved 1264 references, only 11 RCTs were included, four with available results for children/adolescents with autism. Five different cannabis presentations were tested. One trial pointed that cannabis may improve global assessment symptoms, but for other outcomes results were uncertain. No included study assessed quality of life. The certainty of evidence ranged from very low to low certainty for the assessed outcomes. Cannabis whole plant extract may improve global assessment symptoms, but the different cannabis presentations, outcome assessments and very low certainty of evidence from the included studies make it difficult to draw conclusions about cannabis for people with autism. This scenario of uncertainties impacts directly clinical practice and decision making.
🧠 While this systematic review identifies promising signals regarding cannabis derivatives for autism spectrum disorder, clinicians should note several important limitations before considering these agents in practice. The evidence base remains small and heterogeneous, with most studies examining CBD rather than whole-plant cannabis, making it difficult to establish robust dose-response relationships or identify which autism presentations might benefit most. Significant confounders persist including variation in study populations, outcome measures, comorbid conditions like anxiety or epilepsy that may independently respond to cannabinoids, and publication bias favoring positive results. Given these caveats, the current evidence does not yet support cannabis derivatives as first-line therapy, though CBD may warrant consideration as an adjunctive option in carefully selected patients with autism who have failed conventional approaches, particularly when comorbid anxiety or seizures are present. For now, any consideration of cannabinoid therapy in this population should involve shared decision-making with families, discussion of the limited evidence base, and close monitoring given the developmental sensitivity of the adolescent brain.